| Trial ID: | L0551 |
| Source ID: | IRCT201702209662N12
|
| Associated Drug: |
Curcumin
|
| Title: |
Impact of curcumin capsules on serum levels of pro-inflammatory,anti-inflammatory cytokines and cell adhesion molecules in Non-alcoholic fatty liver disease
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Condition 1: Nonalcoholic fatty liver disease (NAFLD). Condition 2: Other specified inflammatory liver diseases. <br>Fatty (change of) liver, not elsewhere classified <br>Other specified inflammatory liver diseases;Fatty (change of) liver, not elsewhere c
|
| Interventions: |
Intervention 1: A number of curcumin capsules daily (500 mg) for 8 weeks. Intervention 2: A number of placebo capsules daily (500 mg) for 8 weeks.;Treatment - Drugs;Placebo;A number of curcumin capsules daily (500 mg) for 8 weeks;A number of placebo cap
|
| Outcome Measures: |
L-selectin. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;E-selectin. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;P-selectin. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;V CAM-1. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;I CAM-1. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;IL-6. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;IL-8. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;IL-1. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;IL-10. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;TNF-a. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;VEGF. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;MCP-1. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.Grade of fatty liver. Timepoint: Before and 8 weeks after intervention. Method of measurement: Ultrasonography.;BMI. Timepoint: Before and 8 weeks after intervention. Method of measurement: Kg/m2.
|
| Sponsor/Collaborators: |
Vice chancellor for research of Isfahan Cardiovascular Research Center
|
| Gender: |
All
|
| Age: |
18 years70 years
|
| Phases: |
Phase 1/Phase 2
|
| Enrollment: |
80
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.
|
| Start Date: |
25/04/2017
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
22 February 2018
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/10233
|
